Anti-NGF antibodies eased chronic pain but increased joint-related harms
Trials found pain and function benefits alongside safety concerns, especially for fasinumab and tanezumab.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Fasinumab and tanezumab improved pain and physical-function scores compared with placebo, but also increased joint-related adverse events and abnormal peripheral sensations. Assessing this balance requires both symptom and safety results. Relative risks alone do not reveal how likely harm is or how many additional patients would experience it.
Long-term safety remains uncertain. The abstract provides no absolute event rates or assessment durations, limiting judgments about the likelihood of harm and how benefits and risks develop over time.
What researchers found
Change in pain score
Fasinumab versus placebo; timeframe unreported. SMD measures differences in standard deviations, using the spread of pain scores as the unit. Negative values favor fasinumab.
Formally assessed joint disorders
Fasinumab versus placebo; timeframe unreported. The estimate means 4.7 times the placebo group's risk; absolute event rates are absent.
Reading benefits alongside harms
The review examined antibodies against nerve growth factor for chronic musculoskeletal pain. It assessed pain and function alongside formally reviewed joint disorders and altered sensation, making safety central to interpreting improvements.
Fulranumab also had tradeoffs
Fulranumab had smaller reported symptom effects versus placebo and a more favorable overall safety profile in this analysis. However, it also increased abnormal peripheral sensations compared with placebo.
The original publication
Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysis.
Abouelella A, Najah Q, Day RO et al.
Drugs · 2026
- PubMed ID
- 41880116
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.